ArticleCancer medicine2026
Linking Targeted Pancreatic Cancer Genes With Metabolic Disorders: A Cross-Species Translational Pathway.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
introductionPancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies because of its typically late diagnosis and limited treatment options, with surgical resection being the primary intervention. Emerging studies have consistently reported associations between PDAC and metabolic dysfunctions, including obesity, chronic inflammation, and diabetes. In this study, we investigated the molecular interplay between PDAC-associated genes and metabolic disorder pathways.
methodsWe analysed publicly available bulk RNA-Seq datasets from human and murine adipose tissues, complemented by single-cell RNA-Seq data from advanced-stage PDAC. A set of key genes, ITGAM, PECAM1, CCL5, STAT1, STAT2, and CD44, was examined for expression patterns across datasets. Unsupervised clustering techniques were applied to single-cell data to identify transcriptionally distinct populations. Functional analyses were conducted using KEGG pathway enrichment and STRING-based protein-protein interaction networks. To experimentally validate transcriptomic findings, we performed ΔCT-based quantitative PCR (qPCR) on human adipose tissue samples.
resultsGene expression analyses revealed significantly high expression of PDAC-associated markers in both obese human and mouse models. Specific single-cell clusters demonstrated transcriptional profiles linked to metabolic dysregulation in PDAC. Enrichment and network analyses implicated diabetic complication pathways and inflammatory signalling cascades. Experimental validation confirmed that genes such as ITGAM, CCL5, CXCL10, STAT1, and STAT2 were significantly upregulated in obese individuals compared to lean controls, underscoring a potential immunometabolic axis in PDAC pathophysiology.
conclusionOur findings highlight a strong association between the upregulation of PDAC recurrence genes and the activation of metabolic pathways linked to obesity, diabetes, and inflammation. The consistent expression patterns across species suggest potential for developing targeted therapies to inhibit these metabolic pathways post-pancreatic cancer resection, potentially reducing fatality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.